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Background
Oncolytic viruses are a promising approach for cancer
therapy. Recent clinical trials proved the safety and anti-
tumor activity of several oncolytic viruses in solid
tumors. However, very little is known about the poten-
tial of the oncolytic viruses to target hematologic malig-
nancies. Careful analysis of the effects of the oncolytic
viruses in patients with hematologic malignancies will
lead to the development of more specific and effective
treatment strategies.
Methods
We studied the abilities of various vaccinia-based oncoly-
tic virus constructs to target and eliminate leukemic cells
derived from patients with several hematologic malignan-
cies. We used vaccinia virus constructs derived from the
LIVP strain, LIVP 1.1.1. strain (plaque purified isolate of
the nonattenuated LIVP strain), and from the WR strain.
The ability of these constructs to infect and amplify in
the patients’ leukemic cells and blast cells was studied
with fluorescent microscopy, flow cytometry, and plaque
assays for viral replication.
Results
We found that our oncolytic virus constructs infected
and killed the patient-derived leukemic cells. The LIVP
1.1.1.-based construct was the most efficient in infecting
the leukemic cells, followed by the WR-based construct
and the LIVP-based constructs. Flow cytometry data
suggested that some of the infected cells have blast-like
characteristics. Importantly, virus infection with the
oncolytic vaccinia virus constructs correlated with the
disease progression in these patients. In all experiments,
the viral amplification and cytotoxicity were significantly
higher in the leukemic cells than in the control healthy
mononuclear cell subsets.
Conclusions
Our findings suggest the potential of our vaccinia-derived
oncolytic virus constructs in targeting different hematolo-
gic malignancies. These findings are very relevant to the
development of optimized clinical grade oncolytic vaccinia
viruses for treatment of hematologic malignancies.
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